Last reviewed · How we verify
Bevacizumab plus Atezolizumab
Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while atezolizumab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), thereby enhancing anti-tumor immune response.
Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while atezolizumab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), thereby enhancing anti-tumor immune response. Used for Non-small cell lung cancer, metastatic or recurrent, Renal cell carcinoma, metastatic, Urothelial carcinoma, locally advanced or metastatic.
At a glance
| Generic name | Bevacizumab plus Atezolizumab |
|---|---|
| Also known as | Avastin plus Tecentriq |
| Sponsor | Ze-yang Ding, MD |
| Drug class | Anti-angiogenic agent and PD-L1 inhibitor |
| Target | VEGF-A and PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bevacizumab works by binding to VEGF-A, preventing its interaction with its receptor and subsequently inhibiting angiogenesis. Atezolizumab, on the other hand, binds to PD-L1, blocking its interaction with the programmed death-1 (PD-1) receptor on T cells, which enhances the anti-tumor immune response.
Approved indications
- Non-small cell lung cancer, metastatic or recurrent
- Renal cell carcinoma, metastatic
- Urothelial carcinoma, locally advanced or metastatic
Common side effects
- Hypertension
- Fatigue
- Nausea
- Diarrhea
- Rash
Key clinical trials
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (PHASE1, PHASE2)
- A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) (PHASE1, PHASE2)
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (PHASE2)
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (PHASE2)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab plus Atezolizumab CI brief — competitive landscape report
- Bevacizumab plus Atezolizumab updates RSS · CI watch RSS
- Ze-yang Ding, MD portfolio CI